彭华研究员
教育经历
1983.08-1989.07，北京大学医学部，预防医学专业，医学学士
1998.08-2004.07，纽约州立大学布法罗分校医学院，微生物学专业，哲学博士
工作经历
1989.07-1996.12，北京儿童医院儿科研究所微生物免疫室，助理研究员
2004.07-2010.07，美国国家卫生研究院（NIH），博士后
2010.08-2023.01，中国科学院生物物理研究所，副研究员/研究员/研究组长
2023.02至今，广州实验室，研究员
研究简介
彭华研究员长期从事病毒与免疫学研究，专注于机体抗病毒感染免疫应答机制研究、病毒相关肿瘤的免疫治疗药物研究、以及抗病毒的预防/治疗性疫苗平台建设，取得重要的系统性的科研与转化成果。研究成果先后发表在Gut, Cell Res., Cell Discov., Sci Immuno., JEM, JCI, Gastro, Nat Commun., PNAS, Nat Med, Nat Immuno., Hepatology, Clin Can Res, JI, JBC, and JV等学术期刊。彭华团队研发了完全自主知识产权的创新型新冠病毒融合蛋白疫苗，并与丽珠生物联合开发新冠疫苗产品（丽康V-01）。该疫苗已于2022年6月获国家批准作为加强针纳入紧急使用，并于2022年9月正式纳入新冠疫苗免疫规划系统。针对新冠变异株的丽珠二价疫苗BV-01-QX于2023年12月又一次获批紧急使用，为后续加强免疫规划接种实施方案提供更优选择。
代表性成果
1. Chao-Yang Meng, Shiyu Sun, Yong Liang, Hairong Xu, Chao Zhang, Min Zhang, Fu-Sheng Wang, Yang-Xin Fu*, Hua Peng*. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut. 2023 Aug;72(8):1544-1554.
2. Shen J#, Zou Z#, Guo J, Cai Y, Xue D, Liang Y, Wang W, Peng H*, Fu YX*. An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. J Exp Med. 2022 Dec 5;219(12): e20220745.
3. Yifan Lin#, Jing Sun#, Xuezhi Cao#, Xiuye Wang, Xi Chen, Hairong Xu, Jincun Zhao*, Yang-Xin Fu* and Hua Peng*. Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2. Cell Discov. 2022; 8: 43.
4. Diyuan Xue#, Benjamin Moon#, Jing Liao, Jingya Guo, Zhuangzhi Zou, Yanfei Han, Shuaishuai Cao, Yang Wang, Yang-Xin Fu*, Hua Peng*. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Science Immunology, 2022 Jan 7;7(67):eabi6899
5. Shiyu Sun#, Xi Chen#, Jingjing Lin, Junwen Ai, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu*, Hua Peng*. Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01. Cell Discov. 2021 Nov 30;7(1):114.
6. Sunshiyu Sun#, Yueqi Cai#, Tian-Zhang Song#, Yang Pu#, Lin Cheng, Hairong Xu, Chaoyang Meng Yifan Lin, Haibin Huang, Fang Zhao, Jing Sun, Silin Zhang, Yu Gao, Jian-Bao Han, Xiao-Li Feng, Dan-Dan Yu, Haidong Tang, Jincun Zhao, Zheng Zhang, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu*, Yong-Tang Zheng*, Hua Peng*. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res. 2021 Sep;31(9):1011-1023.
7. Jingya Guo, Yong Liang, Diyuan Xue, Jiao Shen, Yueqi Cai, Jiankun Zhu, Yang-Xin Fu*, Hua Peng*. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021 Nov;31(11):1190-1198.
8. Sisi Deng, Zhichen Sun, Jian Qiao, Yong Liang, Longchao Liu, Chunbo Dong, Aijun Shen, Yang Wang, Hong Tang, Yang-Xin Fu, and Hua Peng. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells. JCI Insight. 2020;5(7):e132000.
9. Zhichen Sun, Zhenhua Ren, Kaiting Yang, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu*, and Hua Peng*. A next generation tumor-targeting IL-2 preferentially promotes tumor infiltrating CD8+ T cells response and effective tumor control. Nat Commun. 2019 Aug 28;10(1):3874.
10. Yang K, Liang Y, Sun Z, Xue D, Xu H, Zhu M, Fu YX*, Peng H*. J Virol. T cell-derived Lymphotoxin is Essential for anti-HSV-1 Humoral Immune Response. J Virol. 2018 Jun 29;92(14). pii: e00428-18.